FDA Gives Green Light on Post Approval Clinical Study of Surgical Ablation System

Published date : 24 September 2012
Article date : 24 September 2012

Massdevice reports that the FDA has given the go-ahead on AtriCure's post-approval clinical study of its Synergy radiofrequency ablation system in treatment of non-paroxysmal atrial fibrillation, a chronic and hard-to-treat heart disease. 

The new 3-year, 350-patient ABLATE study follows the West Chester, Ohio-based device maker's December 2011 FDA win for the Synergy ablation system, indicated for treatment of AF during open-heart surgery. Previous Synergy studies found that 84% of patients were free from AF at 6 month following treatment, and 75% remained AF-free at 22 months. 

According to the manufacturer, the device was the 1st surgical ablation system approved by the FDA for treating AF and the 1st approved for treating persistent and long-standing persistent AF.  The FDA cleared the Synergy device for cardiac ablation during concomitant open-heart surgical procedures. 

Source: Massdevice 17 September 2012

Read the full article here.

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.